Loading clinical trials...
Loading clinical trials...
A Phase 2a, Open-Label, Sequential Dose Escalation Study to Evaluate the Safety and the Pharmacokinetics of Oral PRX-112 (Plant Recombinant Human Glucocerebrosidase) in Enzyme Replacement Therapy-Naïve Subjects With Gaucher Disease
Conditions
Interventions
PRX-112
Locations
1
Israel
Shaare Zedek Medical Center
Jerusalem, Israel
Start Date
April 1, 2014
Primary Completion Date
December 1, 2015
Completion Date
December 1, 2015
Last Updated
September 28, 2016
NCT07223944
NCT05992532
NCT03333200
NCT06573723
NCT05487599
NCT03190837
Lead Sponsor
Protalix
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions